Endocrine therapy and breast-conserving surgical management without follow-up radiotherapy is safe in low-risk, luminal A subtype breast cancer
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read More
Oncology
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read More
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE)
Bookmark1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer...
Read More
Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
Bookmark1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in...
Read More
Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
Bookmark1. The pathological complete response rate for the experimental group was improved...
Read More
The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer
Bookmark1. At 24 months, more participants in the pembrolizumab group were alive without an event,...
Read More
Several factors contribute to patients’ perception of a good death from cancer
Bookmark1. In this systematic review, seven core elements of a good death among cancer patients...
Read More
Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer
Bookmark1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide...
Read More
Reducing the screening age for colorectal cancer in Canada to 40 or 45 may result in fewer cases, less mortality, and reduced healthcare spending costs
Bookmark1. Initiating colorectal cancer screening at age 45 results in 12,188 fewer cases and...
Read More
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
Bookmark1. The immune subtype demonstrated an improved progression-free survival (HR 0.37) and...
Read More
Spirituality may benefit patients with a diagnosis of prostate cancer
Bookmark1. In this systematic review, most articles reported a positive association between...
Read More
Atezolizumab added to cabozantinib does not improve clinical outcomes in patients with metastatic renal cell carcinoma
Bookmark1. Progression-free and overall survival was comparable in both the intervention and...
Read More
Higher cardiorespiratory fitness may be protective against breast cancer in postmenopausal women
Bookmark1. In this prospective cohort study, higher cardiorespiratory fitness (CRF) was associated...
Read More
Fruquintinib significantly improves survival in patients with refractory metastatic colorectal cancer
Bookmark1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2....
Read More
Checkpoint Inhibitors With Radiotherapy in Patients With Advanced Solid Tumors
Bookmark1. Stereotactic body radiotherapy in addition to immune checkpoint inhibitors has similar...
Read More
Long telomere syndrome is associated with an increased risk of developing neoplasms
Bookmark1. In this case series, protection of telomeres 1 (POT1) mutations associated with long...
Read More
Adjuvant treatment with programmed cell death receptor-1 inhibitor pembrolizumab is an effective adjuvant treatment for stage III/IV melanoma
Bookmark1. Five-year disease-free survival was greater in patients who had ≤10% viable tumour or...
Read More
Gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
Bookmark1. Combination therapy with gemcitabine and docetaxel for patients with metastatic or...
Read MoreYounger age may be a poor prognostic factor in patients with metastatic colon cancer
Bookmark1. In this retrospective cohort study, patients younger than 50 with metastatic colorectal cancer (mCRC) had significantly shorter progression-free survival and overall survival rates compared with those aged 50 to 65...
Read MoreDose-escalated simultaneous integrated boost radiotherapy may increase ipsilateral breast tumor relapse rates
Bookmark1. 5-year ipsilateral breast tumor relapse rates for test group 1 were non-inferior to the control group. However, noninferiority was not shown with test group 2 versus control. 2. Test group 2 was found to have a higher...
Read More